Lymphoma, Non-Hodgkin: all 2,043 studies
Page 11 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.
- Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedNCT05065866Phase 1
- Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin LymphomaActive, not recruitingNCT05053659Phase 1
- Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyActive, not recruitingNCT05044039Phase 1
- A Study of LP-118 in Patients With Advanced TumorsCompletedNCT05025358Phase 1
- Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedNCT05024045Phase 1
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersActive, not recruitingNCT05020678Phase 1
- Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin LymphomaActive, not recruitingNCT05019976Not applicable
- Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular ContractureStatus unknownNCT05017337
- CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's LymphomaStatus unknownNCT05013372Early Phase 1
- CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHLWithdrawnNCT04995536Phase 1
- A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin LymphomasTerminatedNCT04986865Phase 1
- Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort StudyTerminatedNCT04982471
- Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus BiosimilarsCompletedNCT04971304
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT04965493Phase 3
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaStatus unknownNCT04948788Phase 2
- A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell LymphomaCompletedNCT04923789
- Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaStatus unknownNCT04916860Not applicable
- Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T CellsActive, not recruitingNCT04911478
- Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaTerminatedNCT04903197Phase 1
- Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's LymphomaStatus unknownNCT04897477Phase 1/2
- Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDGActive, not recruitingNCT04892667Not applicable
- A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLLCompletedNCT04876092Phase 1
- A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT04860466Phase 1
- Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or RegionCompletedNCT04859920
- Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins LymphomaTerminatedNCT04853329Phase 1
- RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid MalignanciesTerminatedNCT04844086Phase 1
- Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaWithdrawnNCT04836832Phase 1
- RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose RadiotherapyCompletedNCT04827862Phase 2
- Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid MalignanciesStatus unknownNCT04796675Phase 1
- Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin LymphomaTerminatedNCT04775680Phase 1/2
- Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasCompletedNCT04774068Phase 1
- Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade LymphomasStatus unknownNCT04773769Not applicable
- A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesCompletedNCT04772989Phase 1
- Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosisTerminatedNCT04758650Phase 2
- Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaActive, not recruitingNCT04756726Phase 1
- Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)SuspendedNCT04746131Phase 1
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
- A Phase 1 Study of ADI-001 in B Cell MalignanciesTerminatedNCT04735471Phase 1
- Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid MalignanciesActive, not recruitingNCT04732845Phase 1
- CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell LymphomaActive, not recruitingNCT04718883Phase 2
- A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)TerminatedNCT04718675Phase 1/2
- VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)TerminatedNCT04702425Phase 1
- CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.SuspendedNCT04697290Early Phase 1
- Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) PatientsStatus unknownNCT04696705Early Phase 1
- huCART19-IL18 in CD19+ CancersActive, not recruitingNCT04684563Phase 1
- AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT04673617Phase 1/2
- A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.Active, not recruitingNCT04671693Not applicable
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingNCT04662255Phase 3
- A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT04657224Phase 1
- Clinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin LymphomaWithdrawnNCT04641806
- Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaCompletedNCT04640779Phase 1
- Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.Status unknownNCT04639739Early Phase 1
- Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHLStatus unknownNCT04638270Early Phase 1
- CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)Active, not recruitingNCT04637763Phase 1
- Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
- Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin LymphomaStatus unknownNCT04626908Phase 1/2
- CAR-T Cells in Treating Patients With Relapsed or Refractory NHLStatus unknownNCT04626739Early Phase 1
- Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)CompletedNCT04618081
- Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaActive, not recruitingNCT04606433Phase 1
- 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHLCompletedNCT04601831Phase 1/2
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride InjectionCompletedNCT04569838Phase 2
- Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04546620Phase 2
- The clonoSEQ® Watch RegistryTerminatedNCT04545333
- A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT04540796Phase 1
- A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell LymphomaCompletedNCT04539444Phase 2
- Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST StudyActive, not recruitingNCT04537871
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
- Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaActive, not recruitingNCT04526834Phase 1
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingNCT04509700Phase 2
- Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT04502706Phase 1
- Phase 1 First in Human Study of ZN-d5 as a Single AgentCompletedNCT04500587Phase 1
- Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's LymphomaStatus unknownNCT04497688Not applicable
- Haplo Peripheral Blood Sct In GVHD PreventionCompletedNCT04473911Phase 1
- A Retrospective Cohort Study: Influence of MTHFR C677T and A1298C Polymorphisms on the Survival of Pediatric Patients With Non-Hodgkin's LymphomaCompletedNCT04469543
- Interest of a Systematic One-year Monitoring by 18F-FDG PET-CTCompletedNCT04464590
- Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)WithdrawnNCT04456023Phase 2
- Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin LymphomaStatus unknownNCT04447547Not applicable
- Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's LymphomasStatus unknownNCT04435743
- A Single-cell Transcriptome Study in Patients With Non-Hodgkin's LymphomaStatus unknownNCT04434833
- A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT04434196Phase 1
- Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell TherapyCompletedNCT04409314
- A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's LymphomaStatus unknownNCT04370405Phase 2
- Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FLTerminatedNCT04342117
- A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersActive, not recruitingNCT04328844Phase 1
- TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaCompletedNCT04323657Phase 1/2
- A Multicenter Prospective Study of "High Risk" Molecular Typing in Patients With Adult T Lymphoblastic LymphomaStatus unknownNCT04320992
- A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)Status unknownNCT04306887Phase 2
- Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's LymphomasTerminatedNCT04305444Phase 2
- Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownNCT04296461Phase 1
- Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-GlucoseCompletedNCT04292626Phase 1
- Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive LymphomasActive, not recruitingNCT04288726Phase 1
- A Retrospective Cohort Study: The Influence of MTHFR C677T and A1298C on the High-dose Methotrexate-Related Toxicities in Pediatric Patients With Non-Hodgkin LymphomaCompletedNCT04283955
- A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT04281420Phase 1
- Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid TumorsWithdrawnNCT04260009Phase 1/2
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruitingNCT04245839Phase 2
- Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)CompletedNCT04240808Phase 1
- Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHLTerminatedNCT04240704Phase 1
- CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's LymphomaStatus unknownNCT04237428Not applicable
- A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin LymphomaCompletedNCT04232826Phase 1